Cenova Touts Experience In Assessing Risk Of China Drug Development With Aslan Financing
This article was originally published in PharmAsia News
Executive Summary
Taking on the risk of a biotech investment in China takes experience, according to Shanghai-based Cenova Ventures, as a recent Series B finance round with Aslan Pharmaceuticals shows.
You may also be interested in...
China Builds Up Capability To Conduct Oncology First-In-Man Studies
SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market
China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.